Opportunity Information: Apply for RFA CA 17 042
The Research Centers for Improving Management of Symptoms Across Cancer Treatments (IMPACT) (UM1) grant opportunity (RFA-CA-17-042) is a National Institutes of Health (NIH) cooperative agreement funded under the Department of Health and Human Services and linked to the Beau Biden Cancer Moonshot Initiative. It was built around a key scientific priority identified by the Cancer Moonshot Blue Ribbon Panel: implementing integrated, evidence-based symptom management across the full cancer trajectory. In practical terms, the program is meant to move beyond isolated symptom studies and instead support coordinated, real-world research that improves how symptoms are tracked, interpreted, and treated during active cancer treatment and into survivorship.
The central purpose of the FOA is to create and support a Research Consortium focused on the implementation and evaluation of integrated symptom monitoring and management systems within routine cancer care delivery. The emphasis is not only on developing tools or interventions, but on figuring out how to put them into everyday clinical workflows in ways that actually work for patients, clinicians, and health systems. This includes studying how symptom information is collected (often directly from patients), how it is communicated to care teams, how it triggers timely clinical responses, and how those responses are standardized and improved over time. The intended outcome is stronger, generalizable evidence about what implementation strategies succeed in diverse settings, so that symptom control can be improved at scale rather than remaining limited to a few specialized sites.
Because this is a cooperative agreement (UM1), awardees should expect substantial scientific and programmatic involvement from NIH compared with a traditional research project grant. The structure signals an expectation of active collaboration across funded centers and coordination within the consortium, including shared goals, harmonized methods where appropriate, and consortium-wide learning about best practices for integrating symptom management systems into care delivery.
The opportunity is categorized as discretionary funding, with the activity area listed under education and health, and the CFDA number is 93.395. NIH anticipated making about three awards, with an award ceiling of $1,120,000. The FOA was created on October 18, 2017, and had an original application closing date of January 17, 2018. While those dates indicate the original cycle, the summary reflects the program design and intent described in the announcement.
Eligibility was broad and included state, county, and city or township governments; public and state-controlled institutions of higher education; private institutions of higher education; nonprofit organizations with or without 501(c)(3) status (excluding institutions of higher education in those categories); for-profit organizations other than small businesses; small businesses; and additional eligible entities as clarified in the FOA text. This wide eligibility aligns with the program's implementation focus, since effective symptom monitoring and management often requires partnerships that span academic cancer centers, community oncology practices, health systems, technology partners, and organizations positioned to support dissemination and sustainability.
Overall, IMPACT (UM1) was designed to accelerate nationwide improvement in cancer symptom control by funding a small number of coordinated research centers that can rigorously test how integrated symptom monitoring and management systems perform in real care settings. The expected payoff is actionable evidence that helps oncology practices detect symptoms earlier, respond more consistently, reduce symptom burden during treatment, and improve quality of life outcomes for survivors, with findings that can guide broader adoption across the United States.Apply for RFA CA 17 042
- The Department of Health and Human Services, National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Research Centers for Improving Management of Symptoms Across Cancer Treatments (IMPACT) (UM1)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.395.
- This funding opportunity was created on Oct 18, 2017.
- Applicants must submit their applications by Jan 17, 2018. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $1,120,000.00 in funding.
- The number of recipients for this funding is limited to 3 candidate(s).
- Eligible applicants include: State governments, County governments, City or township governments, Public and State controlled institutions of higher education, Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
IMPACT (UM1) Grant (RFA-CA-17-042) - Frequently Asked Questions
What is the IMPACT (UM1) grant opportunity?
The Research Centers for Improving Management of Symptoms Across Cancer Treatments (IMPACT) (UM1) opportunity (RFA-CA-17-042) is a National Institutes of Health (NIH) cooperative agreement funded under the U.S. Department of Health and Human Services and linked to the Beau Biden Cancer Moonshot Initiative. It supports coordinated research centers focused on improving how cancer-related symptoms are monitored and managed across routine care.
Which NIH funding mechanism is used for IMPACT, and what does that imply?
IMPACT uses the UM1 cooperative agreement mechanism. As a cooperative agreement, it indicates substantial scientific and programmatic involvement from NIH compared with a traditional research project grant, along with an expectation of active collaboration among funded centers within a research consortium.
What is the main goal of the FOA?
The central goal is to create and support a Research Consortium that implements and evaluates integrated symptom monitoring and management systems within routine cancer care delivery. The focus is on understanding what makes these systems work in real clinical workflows for patients, clinicians, and health systems.
What scientific priority does this program address?
The program was built around a key scientific priority identified by the Cancer Moonshot Blue Ribbon Panel: implementing integrated, evidence-based symptom management across the full cancer trajectory, including active treatment and survivorship.
Is this program focused on individual symptoms or something broader?
It is intended to move beyond isolated symptom studies. Instead, it supports coordinated, real-world research on integrated systems that improve how symptoms are tracked, interpreted, and treated across care settings and over time.
What does "integrated symptom monitoring and management systems" mean in the context of this FOA?
Based on the FOA summary, it refers to approaches that connect (1) how symptom information is collected (often directly from patients), (2) how that information is communicated to care teams, and (3) how it triggers timely, standardized clinical responses that can be evaluated and improved.
Does the FOA emphasize tool development or implementation in real-world care?
The emphasis is not only on developing tools or interventions, but on figuring out how to put symptom monitoring and management into everyday clinical workflows in ways that work in practice and can be sustained.
What types of research activities are highlighted?
The summary highlights implementation and evaluation activities, including studying how symptom data are collected, shared with care teams, and used to trigger timely clinical responses, as well as how those responses are standardized and improved over time.
What outcomes is the program trying to achieve?
The intended outcome is stronger, generalizable evidence about which implementation strategies succeed in diverse settings, enabling symptom control improvements to be scaled beyond a few specialized sites. The anticipated payoff includes earlier detection of symptoms, more consistent responses, reduced symptom burden during treatment, and improved quality of life for survivors.
Why is the program structured as a consortium?
The cooperative agreement structure signals an expectation of collaboration across funded centers, including shared goals, harmonized methods where appropriate, and consortium-wide learning about best practices for integrating symptom management systems into routine care delivery.
How many awards did NIH anticipate making?
NIH anticipated making about three awards.
What is the award ceiling for this opportunity?
The award ceiling listed in the summary is $1,120,000.
Which federal department and initiative is this opportunity associated with?
It is funded under the Department of Health and Human Services and linked to the Beau Biden Cancer Moonshot Initiative.
What is the CFDA number for this opportunity?
The CFDA number listed is 93.395.
How is the funding categorized?
The opportunity is categorized as discretionary funding, with the activity area listed under education and health.
When was the FOA created and when did it originally close?
The FOA was created on October 18, 2017, and the original application closing date was January 17, 2018. Those dates reflect the original cycle, while the summary describes the overall program design and intent.
Who is eligible to apply, based on the summary provided?
Eligibility was broad and included state, county, and city or township governments; public and state-controlled institutions of higher education; private institutions of higher education; nonprofit organizations with or without 501(c)(3) status (excluding institutions of higher education in those categories); for-profit organizations other than small businesses; small businesses; and other eligible entities as clarified in the FOA text.
Why does the FOA include such broad eligibility?
The summary ties broad eligibility to the implementation focus. Effective symptom monitoring and management often requires partnerships spanning academic cancer centers, community oncology practices, health systems, technology partners, and organizations that can support dissemination and sustainability.
What care settings and phases of care does the program target?
The program targets routine cancer care delivery across the full cancer trajectory, including active cancer treatment and into survivorship.
What does the FOA suggest about how symptom information is obtained?
The summary notes that symptom information is often collected directly from patients, emphasizing patient-reported symptom monitoring as part of integrated systems.
What does the FOA suggest about how clinical teams should use symptom information?
It emphasizes how symptom information is communicated to care teams and how it triggers timely clinical responses, with an interest in standardizing and continuously improving those responses.
What is the overarching rationale for funding only a small number of centers?
IMPACT (UM1) was designed to fund a small number of coordinated research centers capable of rigorously testing integrated symptom monitoring and management systems in real care settings, producing actionable evidence that can guide broader adoption across the United States.
Browse more opportunities from the same category: Education, Health
Next opportunity: Evaluating Post-Flood Sandbar Succession And Species Biodiversity Related To Listed Species Habitat- MNRR
Previous opportunity: NHLBI Research Career Development Program in HIV-Related Heart, Lung, Blood and Sleep Research (K12)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA CA 17 042
Applicants also applied for:
Applicants who have applied for this opportunity (RFA CA 17 042) also looked into and applied for these:
| Funding Opportunity |
|---|
| Coordinating Center for Improving Management of Symptoms Across Cancer Treatments (IMPACT) (U24) Apply for RFA CA 17 043 Funding Number: RFA CA 17 043 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $375,000 |
| Mechanisms of Cancer Drug Resistance and Sensitivity: Coordinating Center (U24) Apply for RFA CA 17 044 Funding Number: RFA CA 17 044 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $350,000 |
| Accelerating Colorectal Cancer Screening and follow-up through Implementation Science (ACCSIS): Coordinating Center (U24) Apply for RFA CA 17 039 Funding Number: RFA CA 17 039 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $400,000 |
| The NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00) Apply for RFA CA 18 001 Funding Number: RFA CA 18 001 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21 - Clinical Trial Not Allowed) Apply for RFA CA 18 002 Funding Number: RFA CA 18 002 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 - Clinical Trial Not Allowed) Apply for RFA CA 18 003 Funding Number: RFA CA 18 003 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $300,000 |
| Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R21 - Clinical Trial Not Allowed) Apply for RFA CA 18 004 Funding Number: RFA CA 18 004 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 - Clinical Trial Not Allowed) Apply for RFA CA 18 005 Funding Number: RFA CA 18 005 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $300,000 |
| Fast-Track Development of Medications to Treat Cannabis Use Disorders (UG3/UH3 Clinical Trial Optional) Apply for PAR 18 221 Funding Number: PAR 18 221 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $1,000,000 |
| Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P01 Clinical Trials Optional) Apply for RFA CA 18 009 Funding Number: RFA CA 18 009 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $150,000 |
| Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P50 Clinical Trials Optional) Apply for RFA CA 18 010 Funding Number: RFA CA 18 010 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $150,000 |
| Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U54 Clinical Trials Optional) Apply for RFA CA 18 008 Funding Number: RFA CA 18 008 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $150,000 |
| Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U01 Clinical Trials Optional) Apply for RFA CA 18 007 Funding Number: RFA CA 18 007 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $150,000 |
| Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 Clinical Trials Optional) Apply for RFA CA 18 006 Funding Number: RFA CA 18 006 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $150,000 |
| NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UG3/UH3, Clinical Trial Optional) Apply for RFA DA 18 020 Funding Number: RFA DA 18 020 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $1,000,000 |
| Administrative Supplements to NCI Grant and Cooperative Agreement Awards to Support Collaborations with the PDX Development and Trial Centers Research Network (PDXNet)(Admin Suppl - Clinical Trial Not Allowed) Apply for PA 18 496 Funding Number: PA 18 496 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $125,000 |
| Identification of Biomarkers of HIV-1 Pathogenesis and Substance Abuse Comorbidity (R01- Clinical Trial Not Allowed) Apply for RFA DA 18 023 Funding Number: RFA DA 18 023 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Distance Learning and Telemedicine Grant Program Apply for RUS 18 01 DLT Funding Number: RUS 18 01 DLT Agency: Department of Agriculture, Utilities Programs Category: Education, Health Funding Amount: $500,000 |
| Administrative Supplements to NCI Grant and Cooperative Agreement Awards to Support Collaborations with the Drug Resistance and Sensitivity Network (DRSN)(Admin Supp Clinical Trial Not Allowed) Apply for PAR 18 752 Funding Number: PAR 18 752 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $250,000 |
| NCI Community Oncology Research Program (NCORP) Community Sites (UG1 Clinical Trial Required) Apply for RFA CA 18 016 Funding Number: RFA CA 18 016 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA CA 17 042", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.